US 12,409,154 B2
Pharmaceutical compositions for use in treating pain
Tien-Tzu Tai, Taipei (TW); Yun-Long Tseng, Taipei (TW); Sheue-Fang Shih, Taipei (TW); Min-Wen Kuo, Taipei (TW); Carl Oscar Brown, Taipei (TW); Hui-Ting Wang, Taipei (TW); Weenee Yeun Ng Jao, Taipei (TW); Pei-Hsien Hu, Tapei (TW); Wan-Ni Yu, Taipei (TW); Keelung Hong, Taipei (TW); Hao-Wen Kao, South San Francisco, CA (US); and Yi-Yu Lin, South San Francisco, CA (US)
Assigned to TAIWAN LIPOSOME COMPANY, LTD., Taipei (TW); and TLC BIOPHARMACEUTICALS, INC., South San Francisco, CA (US)
Appl. No. 17/433,719
Filed by TAIWAN LIPOSOME COMPANY, LTD., Taipei (TW); and TLC BIOPHARMACEUTICALS, INC., South San Francisco, CA (US)
PCT Filed Feb. 26, 2020, PCT No. PCT/US2020/019806
§ 371(c)(1), (2) Date Aug. 25, 2021,
PCT Pub. No. WO2020/176568, PCT Pub. Date Sep. 3, 2020.
Claims priority of provisional application 62/848,286, filed on May 15, 2019.
Claims priority of provisional application 62/810,378, filed on Feb. 26, 2019.
Prior Publication US 2022/0071934 A1, Mar. 10, 2022
Int. Cl. A61K 31/167 (2006.01); A61K 9/127 (2025.01); A61K 47/24 (2006.01); A61P 23/02 (2006.01)
CPC A61K 31/167 (2013.01) [A61K 9/127 (2013.01); A61K 47/24 (2013.01); A61P 23/02 (2018.01)] 18 Claims
 
1. A pharmaceutical composition for treating postsurgical pain, which comprises a lipid-based complex at a pH of 5.5 to 8.0, wherein the lipid-based complex comprises an amide-type anesthetic in a free base form and a neutral saturated phospholipid, wherein a molar ratio of the amide-type anesthetic in a free base form to the neutral saturated phospholipid of the lipid-based complex is between 0.5:1 and 2:1, and wherein the total amount of the amide-type anesthetic in a free base form of the pharmaceutical composition ranges from 10 mg to 800 mg per dose.